{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["80(4)"],"submitter":["Davis M"],"funding":["Pfizer"],"pubmed_abstract":["Background
Older individuals and adults with certain chronic or immunocompromising health conditions are at increased risk of severe respiratory syncytial virus (RSV) disease.Methods
In this phase 3 randomized trial of RSVpreF safety and immunogenicity in 18-59-year-olds at high risk of severe RSV disease, participants were randomized 2:1 to 1 RSVpreF (120 µg) or placebo dose. Primary safety endpoints included reactogenicity events and adverse events (AEs) through 7 days and 1 month after vaccination, respectively, and serious AEs (SAEs) and newly diagnosed chronic medical conditions (NDCMCs) throughout the study. In primary analyses, immunogenicity elicited 1 month after RSVpreF was bridged to a randomly selected subset of ≥60-year-olds receiving RSVpreF from the immunogen"],"journal":["Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"],"pagination":["911-920"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12043053"],"repository":["biostudies-literature"],"pubmed_title":["Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions."],"pmcid":["PMC12043053"],"pubmed_authors":["Doust M","Chaudhry A","Majid-Mahomed Z","Clark J","Stacey H","Almeida NC","Howitt W","Boghara H","Jiang Q","Kalinina E","Mauri M","DeHaan E","Davis M","Onoya M","Wyper H","Hulinsky I","Towner W","Suplicy F","MONeT Study Team","Davis J","Taylor D","Mehta S","Carter M","Anderson AS","Dever M","Gurtman A","Klein T","Rosen J","Rahman F","Lino MM","Mishkin D","Cannon K","Malkin E","Denham D","Neutel J","Howland W","Li W","Sarwar UN","Munjal I","Cooper D","Smith W","Juarez E","Cohen J","Bailey M","Diemert D","Patton M","Swanson KA","DeAtkine D"],"additional_accession":[]},"is_claimable":false,"name":"Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions.","description":"Background
Older individuals and adults with certain chronic or immunocompromising health conditions are at increased risk of severe respiratory syncytial virus (RSV) disease.Methods
In this phase 3 randomized trial of RSVpreF safety and immunogenicity in 18-59-year-olds at high risk of severe RSV disease, participants were randomized 2:1 to 1 RSVpreF (120 µg) or placebo dose. Primary safety endpoints included reactogenicity events and adverse events (AEs) through 7 days and 1 month after vaccination, respectively, and serious AEs (SAEs) and newly diagnosed chronic medical conditions (NDCMCs) throughout the study. In primary analyses, immunogenicity elicited 1 month after RSVpreF was bridged to a randomly selected subset of ≥60-year-olds receiving RSVpreF from the immunogen","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-03T02:40:56.439Z","creation":"2025-07-06T03:05:56.908Z"},"accession":"S-EPMC12043053","cross_references":{"pubmed":["39523547"],"doi":["10.1093/cid/ciae550"]}}